| Literature DB >> 22138435 |
Kenji Ishitsuka1, Naoko Kunami, Hiroo Katsuya, Rumiko Nogami, Chie Ishikawa, Fusanori Yotsumoto, Hiroe Tanji, Naoki Mori, Morishige Takeshita, Shingo Miyamoto, Kazuo Tamura.
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy caused by human T-lymphotropic virus type I (HTLV-1). ABT-737, a small molecule inhibitor of Bcl-2, Bcl-X(L), and Bcl-w, significantly induced apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells, and synergistically enhanced the cytotoxicity and apoptosis induced by conventional cytotoxic drugs. Moreover, ABT-737 significantly inhibited the in vivo tumor growth of an ATLL mouse model. These results suggest that the use of an agent targeting anti-apoptotic bcl-2 family proteins, either alone or in combination with other conventional drugs, represents a novel promising approach for ATLL.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22138435 DOI： 10.1016/j.canlet.2011.11.030
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679